A multidisciplinary team at the University of Miami Miller School of Medicine has developed a breakthrough nanodrug platform that may prove beneficial for rapid, targeted therapeutic hypothermia after traumatic brain injury (TBI).

Their work, published in ACS Applied Materials & Interfaces, demonstrates that intranasal nanovanilloids can lower brain temperature by 2.0° C to 3.6° C for up to three hours in pre-clinical models. The results offer a promising new approach for protecting the brain at the point of injury.

Dr. Sylvia Daunert
Dr. Sylvia Daunert credited collaboration as a key role in her team’s research success.

“This work exemplifies how nanotechnology and neuroscience principles can be applied together to create therapeutic solutions for critical medical problems that have the potential of saving human lives,” said Sylvia Daunert, Ph.D., Lucille P. Markey Chair in Biochemistry and Molecular Biology and director at the Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute (BioNIUM), one of the study’s lead investigators.

Study Overview: From Chemistry to Clinical Potential

Vanilloids are natural compounds that activate the TRPV1 receptor, which is involved in pain, inflammation and body temperature regulation. The Miller School researchers created nanovanilloids using three cooling compounds: rinvanil, arvanil and olvanil. They used a special process that mixes the drug in alcohol with water while applying sound waves, which helps the particles form and stay evenly sized. Tests showed these particles are very small (all smaller than 200 nanometers), consistent in size and can stay stable for a long time at room temperature.

Importantly, these particles don’t need any extra carriers or coatings. The drug itself forms the particle. This means more medicine can be delivered safely and easily through the nose to reach the brain in a faster and more targeted manner.

The team checked if the nanovanilloids were safe for cells and didn’t cause stress or damage. They found that the particles didn’t harm cell health or increase stress levels. To make sure the nanovanilloid drugs worked as intended, they ran tests showing that the particles activated the target receptor, TRPV1, which is needed to trigger cooling in the brain.

Why the intranasal route?

Delivering the medicine through the nose lets it reach the brain quickly and avoids being filtered out by the body’s usual barriers. This means the treatment works faster and needs a smaller dose compared to giving it through an IV. The research team used a custom designed, 3D-printed spray nozzle to make sure the nanodrug was spread evenly and gently inside the nose.

The researchers also pointed out that similar nasal spray devices are already used for other brain medicines. These devices can be made safely and consistently by following standard manufacturing and quality controls.

Landscape infographic in University of Miami orange and green titled ‘Nanovaanilloids and Temperature.’ The left side shows an orange-and-cream thermometer icon with the text ‘2 °C’ and the caption ‘Nano‑olvanil reduction in head temperature.’ The right side shows a similar thermometer icon with the text ‘3.6 °C’ and the caption ‘Nano‑rinvanil reduction in brain temperature.’ The design uses clean, high‑contrast colors for readability

Using the device, the team administered nanovanilloids and found:

• Nano-olvanil reduced head temperature by about 2 °C for more than 100 minutes for pre-clinical models with no injury.

• Nano-rinvanil achieved a 3.6 °C drop in brain temperature in pre-clinical models with moderate TBI, with core body temperature remaining stable. That indicated targeted brain cooling, and researchers confirmed no liver or kidney toxicity.

Implications for Patient Care

• Prehospital neuroprotection: Enables rapid brain cooling at the scene or during transport for TBI, spinal cord injury, stroke or heat-related illness.

• Targeted therapy: Localized cooling minimizes systemic side effects, a major limitation of traditional hypothermia methods.

• Scalable platform: The carrier-free nano-assembly approach can be adapted for other hydrophobic drugs, broadening its impact on acute neurological care.

“This approach offers a new pathway to protect the brain during the most critical window, with the potential to improve survival and recovery for patients,” said lead investigator Helen Bramlett, Ph.D., professor of neurological surgery at the Miller School and The Miami Project to Cure Paralysis.

Next Steps

The Miller School researchers plan to advance this technology toward clinical translation, including dose optimization, device compatibility and human factors testing. Their work sets the stage for innovative, patient-first neuroprotection strategies that could be deployed outside hospital settings.

Dr. W. Dalton Dietrich in his white coat in his lab
Dr. W. Dalton Dietrich says the Miller School’s nanodrug research could open new avenues for therapeutic hypothermia.

“In my opinion, these results mark one of the most important technological developments in therapeutic hypothermia and targeted temperature management research over the past 30 years,” said W. Dalton Dietrich, Ph.D., scientific director of The Miami Project and professor of neurological surgery and senior associate dean for team science at the Miller School.

“It is important to highlight that the developed technology stems from a team science approach, and that without a multidisciplinary team of scientists, complex problems like this cannot be solved,” Dr. Daunert said.

The Miller School Research Team

The research team was led by Dr. Daunert, Dr. Dietrich, Dr. Bramlett and Sapna Deo, Ph.D., professor of biochemistry and molecular biology at the Miller School.

Dr. Helen Bramlett
Dr. Helen Bramlett
Dr. Sapne Deo in white clinic coat, standing in a medical laboratory
Dr. Sapna Deo

Other key contributors included:

• Emre Dikici, Ph.D., senior scientist and director of the Bionanotechnology Laboratory

• Alexia Kafkoutsou, a Ph.D. candidate in the Department of Biochemistry and Molecular Biology

• Jorge David Tovar, a Ph.D. candidate in the Department of Biochemistry and Molecular Biology

• Juliana Sànchez, M.D., assistant scientist at the Miami Project to Cure Paralysis

Read The Article

News